KyungDong Pharm home
Prescription Medicines

ToWinH Syrup

Product Category
Antitussive expectorant
Active Ingredients
In 20 mL, 10 mg of dihydrocodeine tartrate (BP), 26.2 mg of DL-methylephedrine hydrochloride (KP), 3 mg of chlorpheniramine maleate (KP), 200 mg of ammonium chloride (BP).
Appearance
Red, aromatic sweet syrup in a plastic bottle or aluminum foil pouch
Reimbursement Code
Stick: 648103481
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 pack (20mL)
- Active ingredients:
Dihydrocodeine Tartrate (BP) --------------------------- 10mg
Chlorpheniramine maleate (KP) ------------------------------------ 3mg
DL-methylephedrine hydrochloride (KP) ---------------------------------- 26.2mg
Ammonium chloride (BP) ------------------------------------------------ 200mg
- Additives (preservatives):
Methylparaben --------------------------------------- 0.2mg
Propylparaben ------------------------------------- 1.8mg
- Additives (tar coloring): Red No. 40
- Other additives: D-sorbitol liquid, pomegranate flavor (SH-09-0788), sucralose, stevion 100S, sodium citrate hydrate, citric acid hydrate, sodium edetate hydrate, purified water

2. Effectiveness
cough, phlegm

3. Dosage and dosage
Administer the following dose orally 3 to 4 times a day after meals and at bedtime.
Adults and adolescents over 15 years old: 20mL per time
Children: 1 time
Over 12 years old ~ under 15 years old: 13mL

4. Precautions for use
1. Warning
Avoid administering to patients under 18 years of age who are obese, have obstructive sleep apnea syndrome, or have severe lung disease, as this may increase the risk of severe respiratory depression.

2. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its components
2) Patients taking MAO inhibitors (antidepressants, antipsychotics, emotion regulators, anti-Parkinson drugs, etc.) or within 2 weeks of stopping taking them
3) Children under 12 years of age (refer to ‘Administration to Children’ section)
4) Nursing mothers
5) Patients with glaucoma (anticholinergic action may increase intraocular pressure and worsen glaucoma)
6) Patients with lower urinary tract obstructive diseases such as prostatic hypertrophy

3. Administer with caution to the following patients.
1) People who have a constitution that makes them, their parents, or siblings prone to hives, contact dermatitis, allergic rhinitis, migraines, food allergies, etc.
2) People who have ever experienced allergic symptoms (e.g. fever, rash, joint pain, itching, etc.) due to medication
3) People with liver disease, kidney disease, thyroid disease, diabetes, etc., weak people, or people with high fever
4) Patients with cardiovascular diseases such as circulatory system disease, high blood pressure, or elderly people
5) Women who are pregnant or may be pregnant
6) Patients with increased intraocular pressure or urinary disorders
7) People who are receiving treatment from a doctor
8) People with the following cough:
Cough associated with smoking, asthma, chronic bronchitis, emphysema, bronchiectasis or excessive sputum; cough lasting more than one week or recurring; chronic cough; or cough accompanied by fever, rash or a persistent
cough accompanied by headache
9) Patients with stenotic peptic ulcer or pyloroduodenal obstruction (symptoms may worsen due to inhibition of smooth muscle movement and hypotonia due to the anticholinergic action of chlorpheniramine)
10) Epilepsy patients

4. Adverse reactions
1) Shock: Cyanosis, difficulty breathing, chest discomfort, decreased blood pressure, etc.
2) Hypersensitivity reaction: rash, redness, itching, photosensitivity reaction, exfoliative dermatitis, urticaria, single contraction, muscle weakness, inability to cooperate.
3) Digestive system: nausea, vomiting, constipation, loss of appetite, dry mouth (persistent or severe), heartburn, indigestion, abdominal pain, diarrhea
4) Mental nervous system: dizziness, anxiety, tremors, insomnia, drowsiness, sedation, nervousness, headache, nervousness, double vision, tinnitus, vestibular disorder, strange situation perception, emotional instability, hysteria, tremor, neuritis, coordination abnormality,
Paresthesia, blurred vision, decreased concentration, fatigue, convulsions, confusion
5) Urinary system: Difficulty urinating, frequent urination, urinary retention, urinary retention
6) Circulatory system: hypotension, palpitations, tachycardia, arrhythmia, extrasystoles, hepatitis, jaundice.
7) Respiratory system: dryness of nose or airway, viscous secretion of tracheal secretions, wheezing, nasal congestion
8) Blood system: hemolytic anemia, thrombocytopenia, aplastic anemia, agranulocytosis
9) Others: Chills, sweating abnormalities, chest pain, fatigue, menstrual abnormalities

5. General precautions
1) Avoid driving a car or operating machinery as you may feel drowsy while taking it.
2) Do not overdose or use for a long period of time.

6. Interaction
1) Do not administer in combination with the following medicines: other antitussive expectorants, cold medicines, antihistamines, sedatives, etc.
2) Combined use of alcohol and central nervous system depressants may cause drowsiness.
3) Chlorpheniramine can cause phenytoin toxicity by inhibiting phenytoin metabolism.

7. Administration to pregnant and lactating women
1) Safety for pregnant women and women who may be pregnant has not been established, so only when the benefits of treatment are judged to outweigh the risks.
Administer with caution.
2) This drug suppresses milk secretion and may pass into breast milk, so do not administer to nursing mothers.

8. Administration to children
1) Be especially careful as overdosing in children may cause hallucinations, excitement, convulsions, and death.
2) It should not be administered to children under 12 years of age as severe respiratory depression may occur. (Children under 12 years of age are highly susceptible to respiratory depression. Deaths occur in children under 12 years of age.
There are overseas reports that the risk of severe respiratory depression, including respiratory depression, is high.

8. Administration to elderly people
In general, elderly people have reduced physiological function, so the patient's condition must be observed and administered with caution.

9. Treatment in case of overdose
The lethal dose of chlorpheniramine is 25 to 50 mg per kg of body weight. Symptoms include sedation, abnormal stimulation of the central nervous system, addictive psychosis, convulsions, apnea, delirium, anticholinergic effects,
Ataxia, arrhythmia, and cardiovascular collapse may occur, and in this case, vomiting is induced using laxative syrup or gastric lavage is performed.

10. Precautions for storage and handling
1) Store in a place out of reach of children.
2) Avoid direct sunlight and store tightly in a cool place with as little moisture as possible.
3) To prevent misuse and preserve quality, do not replace the product in another container.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
20mL/stick

7. Expiration date
24 months from date of manufacture (stick)

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2ToWinH SyrupTwo-Win Hitch Syrup (Dosage, Precautions for Use...2018.01.11PDFTwo-Win Hitch Syrup - Dosage and precautions for use.pdf
1ToWinH SyrupTwo-Win Hitch Syrup (Dosage, Precautions for Use...2016.02.23HWP2014 Pharmaceutical Literature Re-evaluation (Twin Hitch Syrup).hwp